Literature DB >> 3032650

A comparison of the neurochemical and behavioral effects of clenbuterol and desipramine.

K T Finnegan, M M Terwilliger, P A Berger, L E Hollister, J G Csernansky.   

Abstract

Because both long-term adrenoceptor agonist administration and antidepressant treatment in animals down-regulate CNS beta-adrenoceptors and attenuate brain adenylate cyclase activity, beta-adrenoceptor agonists may also possess antidepressant properties. We compared the effects of the centrally acting beta-adrenoceptor agonist clenbuterol (5, 10 and 35 mg/kg per day), and the combination of propranolol (5 mg/kg per day) and clenbuterol (10 mg/kg per day), with desipramine (15 mg/kg per day) on forced swim test performance and on cortical beta-adrenoceptors in rats following 7 days of drug administration. Desipramine (15 mg/kg per day), and clenbuterol (10 and 35 mg/kg per day, but not 5 mg/kg per day) both significantly reduced immobility in the forced swim test. Frontal cortex beta-adrenoceptors were significantly down-regulated after desipramine and all 3 doses of clenbuterol. The co-administration of propranolol (5 mg/kg per day) blocked both the reduction in immobility and down-regulation of cortical beta-receptors induced by clenbuterol (10 mg/kg per day). Propranolol (5 mg/kg per day) alone up-regulated frontal cortex beta-adrenoceptors, but had no significant effect on swimming performance. These data suggest that the physiological consequences of beta-adrenoceptor down-regulation are important in the mechanism of action of antidepressants. The results also suggest that clenbuterol may be useful in the treatment of depression.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3032650     DOI: 10.1016/0014-2999(87)90158-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Antagonism of the antidepressant-like effects of clenbuterol by central administration of beta-adrenergic antagonists in rats.

Authors:  Han-Ting Zhang; Ying Huang; James M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  2003-07-25       Impact factor: 4.530

2.  β-adrenergic receptor mediation of stress-induced reinstatement of extinguished cocaine-induced conditioned place preference in mice: roles for β1 and β2 adrenergic receptors.

Authors:  Oliver Vranjkovic; Shona Hang; David A Baker; John R Mantsch
Journal:  J Pharmacol Exp Ther       Date:  2012-05-16       Impact factor: 4.030

3.  Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.

Authors:  Han-Ting Zhang; Ying Huang; Kathleen Mishler; Sandra C Roerig; James M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

Review 4.  Is the forced swimming test a suitable model for revealing antidepressant activity?

Authors:  F Borsini; A Meli
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  Analysis of region-specific changes in gene expression upon treatment with citalopram and desipramine reveals temporal dynamics in response to antidepressant drugs at the transcriptome level.

Authors:  Magdalena Gąska; Maciej Kuśmider; Joanna Solich; Agata Faron-Górecka; Małgorzata J Krawczyk; Krzysztof Kułakowski; Marta Dziedzicka-Wasylewska
Journal:  Psychopharmacology (Berl)       Date:  2012-05-01       Impact factor: 4.530

6.  Pharmacologic specificity of antidepressive activity by monoaminergic neural transplants.

Authors:  D D Dougherty; C E Sortwell; J Sagen
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

7.  Differential sensitivity to the effects of albuterol on locomotor activity and operant behavior.

Authors:  J M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Effects of the beta-2 adrenergic agonist zinterol on DRL behavior and locomotor activity.

Authors:  J M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.